Activin A/Follistatin System: Another Link to Heparin-induced Osteoporosis? [3]

Clinical and Applied Thrombosis/Hemostasis

Volumn 10, Issue 2, 2004, Pages 191-192

  Borawski, Jacek ^a   Naumnik, Beata ^a   Myśliwiec, Michał ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; ENOXAPARIN; FOLLISTATIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

BONE METABOLISM; DRUG INDUCED DISEASE; DRUG MECHANISM; HEMODIALYSIS; HEPARINIZATION; HUMAN; LETTER; MAINTENANCE THERAPY; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL;

ACTIVINS; FOLLISTATIN; HEPARIN; HUMANS; OSTEOPOROSIS; RENAL DIALYSIS;

EID: 1842852125     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960401000213     Document Type: Letter

References (14)

1. Vale W, Rivier J, Vaughan J, et al. Purification and isolation of an FSH releasing protein from porcine follicular fluid. Nature 1986;321:776.
2. Robertson DM, Klein R, de Vos FL, et al. The isolation of polypeptides with FSH suppressing activity from bovine follicular fluid which are structurally different to inhibin. Biochem Biophys Res Commun 1987;149:744.
3. Chen YG, Lui HM, Lin SL, et al. Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp Biol Med 2002;227:75.
4. Shav-Tal Y, Zipori D. The role of activin A in regulation of hemopoiesis. Stem Cells 2002;20:493.
5. Phillips DI, Jones KL, Scheerlinck JY, et al. Evidence for activin A and follistatin involvement in the systemic inflammatory response. Mol Cell Endocrinol 2001;180:155.
6. Molloy CJ, Taylor DS, Pawlowski JE. Novel cardiovascular actions of the activins. J Endocrinol 1999;161:179.
7. Naumnik B, Borawski J, Myśliwiec M. Activin A/follistatin-new cytokines, new perspectives. Pol Arch Med Wewn 2003;4:431.
8. Sakai R, Eto Y. Involvement of activin in the regulation of bone metabolism. Mol Cell Endocrinol 2001;180:183.
9. Sakai R, Fujita S, Ilorie T, et al. Activin increases bone mass and mechanical strength of lumbar vertebrae in aged overiectomized rats. Bone 2000;27:91.
10. Borawski J, Naumnik B, Myśliwiec M. Hepatocyte growth factor: A possible mediator of heparin-induced osteoporosis? Clin Appl Thromb Hemost 2003;9:171.
11. Phillips DJ, Jones KL, McGaw DJ, et al. Release of activin and follistatin during cardiovascular procedures is largely due to heparin administration. J Clin Endocrinol Metab 2000;85:2411.
12. Borawski J, Naumnik B, Myśliwiec M. Activation of hepatocyte growth factor/activin A/follistatin system during hemodialysis: Role of heparin. Kidney Int 2003;64:2229.
13. Sandset PM, Bendz B, Hansen JB. Physiological function of tissue factor pathway inhibitor and interaction with heparins. Haemostasis 2000;30(Suppl 2):48.
14. Naumnik B, Borawski J, Myśliwiec M. Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis. Nephrol Dial Transplant 2003;18:1376.